MABTAS (Rituximab) belongs to a group of cancer drugs known as monoclonal antibodies . MABTAS is used to treat several types of CD20-positive NHL (non-Hodgkin lymphoma ). It may also be used to treat blood cancer -CLL (Chronic lymphocytic leukemia) and Rheumatoid arthritis. This drug is administered only as an IV infusion. MABTAB is a prescription drug .
Manufacturer : Intas Pharmaceuticals Ltd
Strengths available : 100mg & 500mg
- Administer only as an Intravenous Infusion.
- Do not administer as an intravenous push or bolus.
- Premedicate before each infusion.
Mabtas should only be administered by a healthcare professional with appropriate medical support to manage severe infusion reactions that can be fatal if they occur.
First Infusion: Initiate infusion at a rate of 50 mg/hr. In the absence of infusion toxicity, increase infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
Subsequent Infusions: Initiate infusion at a rate of 100 mg/hr. In the absence of infusion toxicity, increase rate by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr.
Most common side effects are Headache, Weakness, Edema, Infection, Hair loss, Itching, Chills, Febrile neutropenia, Decreased white blood cell count (neutrophils), Infusion reaction.
Pack of 1 Vial
3S Corporation is a WHO GDSP approved & licensed Pharmaceutical stockist/wholesaler/distributor/exporter/importer of MABTAS Rituximab 100mg & 500 based in India - To buy MABTAS Rituximab 100mg & 500 or know its cost price contact us here.
We supply & sell MABTAS Rituximab 100mg & 500 for Reference Listed Drugs, Government Tenders, Shortage Lists, Emergency Imports, Name Patient Drugs, Comparator Drug Studies, Un-licensed Importation, clinical trial samples & Bio-Similars.